Microscopic examination of thick and thin blood smears
stained
with Giemsa dye is considered the primary diagnostic tool for the
confirmation and management of suspected clinical malaria. However,
detecting gametocytes is relatively insensitive, particularly in asymptomatic
individuals with low-density Plasmodium infections.
To complement existing diagnostic methods, a rapid and ultrasensitive
point-of-care testing (POCT) platform for malaria detection is urgently
needed and necessary. A platform based on recombinase polymerase amplification
(RPA) followed by CRISPR/Cas12a (referred to as RPA-CRISPR/Cas12a)
was developed and optimized for the determination of Plasmodium spp. parasites, particularly
Plasmodium falciparum, using a fluorescence-based assay (FBDA), lateral flow
test strips (LFTS), or naked eye observation (NEO). Then, the established
platform was assessed with clinical malaria isolates. Under optimal
conditions, the detection threshold was 1 copy/μL for the plasmid,
and the limit of detection was 3.11–7.27 parasites/μL
for dried blood spots. There was no cross-reactivity against blood-borne
pathogens. For the accuracies of RPA-CRISPR/Cas12a, Plasmodium spp. and
P. falciparum
testing were 98.68 and 94.74%, respectively. The method was consistent
with nested PCR results and superior to the qPCR results. RPA-CRISPR/Cas12a
is a rapid, ultrasensitive, and reliable platform for malaria diagnosis.
The platform requires no or minimal instrumentation for nucleic acid
amplification reactions and can be read with the naked eye. Compared
with similar diagnostic methods, this platform improves the reaction
speed while reducing detection requirements. Therefore, this platform
has the potential to become a true POCT for malaria parasites.